BRNS - Company ID 0001828185
The table below shows Barinthus Biotherapeutics plc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$47.98M | -$28.94M | -$50.92M | -$14.43M | -$32.58M | -$11.03M |
| Capital expenditure | $37.00K | $892.00K | $5.41M | $6.14M | $1.15M | $293.00K |
| Investing cash flow | $416.00K | -$892.00K | -$5.41M | -$5.75M | -$12.91M | -$293.00K |
| Dividends paid | - | - | - | - |
Barinthus Biotherapeutics plc. reported operating cash flow of -$47.98M for fiscal year 2025. That is down 65.8% from -$28.94M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$11.03M (FY 2020) to -$47.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.00K | $2.16M | $1.87M | $325.00K | $222.74M | $41.44M |